Loading
Breast Cancer Treatment Studies / Breast Lesions and Carcinomas / Digital Radiography and Breast Imaging · Journal article
Breast Cancer Research · August 13, 2026
Well-designed and adequately powered for the question it asks.
In this large prospective UK cohort, high breast density, current menopausal hormone therapy use, later age at menopause, history of benign breast disease, underweight status at age 20, and family history of breast cancer were each independently associated with increased risk of interval breast cancer compared to screen-detected cancer. Being overweight was protective. These associations persisted after adjustment for tumour characteristics and were independent of each other.
Prospective cohort case–case study. 1,940 women diagnosed with breast cancer between 2004 and 2018 after enrolment in the prospective UK cohort; 1,185 screen-detected, 755 interval-detected. Breast density measured in 1,191 cases.. Intervention: Prospective assessment of breast density and reproductive, hormonal, lifestyle, and medical risk factors prior to cancer diagnosis. Compared with: Interval breast cancer cases versus screen-detected breast cancer cases. n = 1,940. United Kingdom.
High breast density (Q4 vs Q1) associated with 2.13-fold increased IBC risk (95% CI 1.44–3.17) Current menopausal hormone therapy use increased IBC risk 1.41-fold (95% CI 1.04–1.91) vs. never users Later menopause (≥55 vs. <50 years) increased IBC risk 1.60-fold (95% CI 1.02–2.50)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and screening programmes should consider incorporating breast density assessment and risk stratification based on menopausal hormone therapy use, menopause age, BMI history, and personal/family history to identify women at higher risk of interval cancer and potentially modify screening intervals or modality. The identification of modifiable factors (particularly current MHT use and weight) offers opportunities for risk reduction counselling.
Large prospective cohort study with detailed pre-diagnostic risk factor assessment and breast density measurement in a UK screening population, yielding clear odds ratios for interval cancer risk across multiple independent variables.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and screening programmes should consider incorporating breast density assessment and risk stratification based on menopausal hormone therapy use, menopause age, BMI history, and personal/family history to identify women at higher risk of interval cancer and potentially modify screening intervals or modality. The identification of modifiable factors (particularly current MHT use and weight) offers opportunities for risk reduction counselling.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Background Interval breast cancers (IBC), diagnosed between routine screening rounds, tend to have a worse prognosis than screen-detected breast cancers (SDBC). Identifying risk factors for IBCs is critical for improving early detection and developing risk-stratified screening strategies to reduce their incidence. We evaluated associations of breast density, reproductive, hormonal, lifestyle and medical factors with IBC compared to SDBC in a large UK cohort. Methods Analyses included 1,940 women diagnosed with breast cancer between 2004 and 2018 after enrolment in the Breast Cancer Now Generations Study, a prospective UK cohort linked to the National Health Service Breast Screening Programme. Pre-diagnostic risk factors were collected at enrolment, and breast density was estimated from pre-diagnostic mammograms using Cumulus in a subset of 1,191 cases. Risk factor associations with density were estimated using linear regression models. We identified 1,185 SDBCs and 755 IBCs included in logistic regression models to estimate odds ratios (OR) and 95% confidence intervals (CI) for associations between risk factors and IBC, adjusting for age at diagnosis, time since recruitment and year of diagnosis, breast density and tumour characteristics. Results Higher breast density was associated with later age at menarche, nulliparity, breastfeeding, history of benign breast disease (BBD), alcohol consumption, lower body mass index (BMI) at recruitment and at age 20, and current use of menopausal hormone therapy (MHT). In a fully-adjusted model, IBC risk was lower for overweight women (OR (95% CI ) = 0.74 (0.58–0.93) vs. normal weight), and higher for high breast density (2.13 (1.44–3.17) for Q4 vs. Q1), later age at menopause (1.60 (1.02–2.50) 55 + vs. < 50), current MHT use (1.41 (1.04–1.91) vs. never users), history of BBD (1.36 (1.11–1.68)), being underweight at age 20 (1.65 (1.14–2.38) vs. normal weight), family history of breast cancer (1.26 (1.00–1.58)) and ever using oral contraceptives (1.25 (0.93–1.69) vs. never). These risk factor associations were independent of tumour characteristics. Conclusions Breast density and several risk factors independently increase the likelihood of IBC, highlighting opportunities for tailored screening strategies to enhance early detection and reduce IBCs incidence.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.